Abstract
Since Bortezomib was approved by US FDA as the first drug to treat multiple myeloma, various boronic acid compounds have been developed as enzyme inhibitors. This paper reviewed the progress of boronic acid-based inhibitors against enzymes including proteasome, serine protease, HDACs and other enzymes in the past decade.
Keywords: Boronic acid, bortezomib, enzyme inhibitor, HDACs, proteasome inhibitor, serine protease.
Current Medicinal Chemistry
Title:Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress
Volume: 21 Issue: 28
Author(s): H. Fu, H. Fang, Jie Sun, H. Wang, A. Liu, J. Sun and Z. Wu
Affiliation:
Keywords: Boronic acid, bortezomib, enzyme inhibitor, HDACs, proteasome inhibitor, serine protease.
Abstract: Since Bortezomib was approved by US FDA as the first drug to treat multiple myeloma, various boronic acid compounds have been developed as enzyme inhibitors. This paper reviewed the progress of boronic acid-based inhibitors against enzymes including proteasome, serine protease, HDACs and other enzymes in the past decade.
Export Options
About this article
Cite this article as:
Fu H., Fang H., Sun Jie, Wang H., Liu A., Sun J. and Wu Z., Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress, Current Medicinal Chemistry 2014; 21 (28) . https://dx.doi.org/10.2174/0929867321666140601200803
DOI https://dx.doi.org/10.2174/0929867321666140601200803 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design New Generation of Liposomal Drugs for Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Circulating Tumor Cells (CTCs) as a Liquid Biopsy Material and Drug Target
Current Drug Targets Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
Current Drug Targets Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Identification of Marker Genes for Cancer Based on Microarrays Using a Computational Biology Approach
Current Bioinformatics Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics
Current Medicinal Chemistry EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine Cisplatin Properties in a Nanobiotechnological Approach to Cancer: A Mini-Review
Current Cancer Drug Targets Isoniazid: Metabolic Aspects and Toxicological Correlates
Current Drug Metabolism Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date
Recent Patents on Biomarkers Roles of Tumor Microenvironment in Hepatocelluar Carcinoma
Current Cancer Therapy Reviews Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients Over a 4 Year Period
Current Drug Therapy Regulatory Role of the α7nAChR in Cancer
Current Drug Targets Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Exploiting Innate γδ T Lymphocytes for Tumor Immunotherapy
Recent Patents on Biomarkers